Obermatt
See Similar Stocks →

Sartorius Stedim

PAR:DIM · FR0013154002
Life Sciences Tools & ServicesLarge

360

15
EV / EBIT25
Price / Owner Earnings6
Owner Earnings Yield45
Dividend Yield33
Price/Sales19
EV / Gross Profit25
Price/Book31
Return on Capital53
Cash Return on Capital43
Return on Equity56
EBIT Margin65
Gross Profitability37
Cash Conversion76
Accruals54
Owner Earnings Margin49
Sales growth70
Profit Growth81
Long-Term EPS Growth90
Owner Earnings Growth27
Reinvestment39
Price momentum43
Debt load36
Refinancing15
Debt Payback10
Liquidity40
Analyst ratings81
Opinion Changes50
Price Target Upside75
Market mood41
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Sartorius Stedim generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryGermany
IndustryLife Sciences Tools & Services
SizeLarge
TypePublic Company
ExchangeENXTPA
Founded1978
Employees2,353
Websitesartorius.com/en/company/about-sartorius-stedim-biotech-sa
ISINFR0013154002
Last UpdateApr 2, 2026
Indices
CAC All (France)SBF 120 (France)
Themes
Health DiagnosticsPredictive Analytics

Description

Sartorius Stedim Biotech S.A. emphasizes its role as a key player in biopharmaceutical research and manufacturing. The company offers comprehensive solutions, including products and services that facilitate the development and production of biotech…

Analysis

Hope premium

Sartorius Stedim Biotech S.A. is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

On valuation, the picture is expensive. The owner-earnings multiple stands at 149.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 34% a year, against analyst forecasts of 23%. The market is pricing in far more than analysts expect: heroic expectations.

Growth is moderate; the safety picture is stretched. The company scores 14/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
12
2023202420252026

All-time high

46

Oct 2025

All-time low

1

Jan 2024

Average rank

24

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
19
9
12
7
Price/Earnings
20
14
12
28
Price/Book
31
19
14
8
Dividend Yield
33
29
28
28
Value (overall)
19
16
7
15

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sartorius Stedim with its peers
Lonza
VTX:LONN
54
CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Tecan Group
SWX:TECN
25
CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Exosens
PAR:EXENS
49
CountryLuxembourg
IndustryAerospace & Defense
SizeMedium
Full Stock Analysis →
Hexagon Composites
OSL:HEX
6
CountryNorway
IndustryMachinery
SizeSmall
Full Stock Analysis →
Sartorius
GER:SRT
11
CountryGermany
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
SCHOTT Pharma AG & Co
GER:1SXP
62
CountryGermany
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →